Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
27 authors.
Ander de BlasCancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0001-8545-2441
Massimo AndreattaDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-8036-2647
Asier Antoñana-VildosolaCancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0002-1404-6398
Paloma Velasco-BeltránCancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0001-9686-5903
Leire Egia-MendikuteCancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0002-6435-1219
Borja Jiménez-LasherasCancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0002-1181-7492
Alexandre BoschCancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0002-3022-7463
Adrián Barreira-ManriqueCancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0001-9893-6701
Iker OyenarteCancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0002-2870-3344
So Young LeeCancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0003-3130-785X
Christoph Heuser-LoyDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.ORCID 0000-0003-1410-7573
Jeremy G BaldwinDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.ORCID 0000-0002-0367-8939
Roland C SchelkerDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.ORCID 0000-0002-3466-5866
Azucena Martín-SantosDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.ORCID 0009-0000-2422-6264
Fabio MastrogiovanniDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.ORCID 0009-0003-3067-6263
Mikel AzkargortaProteomics Platform, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0001-9115-3202
Felix ElortzaProteomics Platform, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0001-8839-5438
James D SutherlandUbiquitin-likes and Development Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0003-3229-793X
Veronica TorranoDepartment of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), Bilbao, Spain.ORCID 0000-0002-4252-1977
Ana M AransayGenome Analysis Platform, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0002-8271-612X
Lorena Pérez-GutiérrezCancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0001-8135-4975
Alena GrosTumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0002-1207-1880
Santiago J CarmonaDepartment of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-2495-0671
Luca GattinoniDivision of Functional Immune Cell Modulation, Leibniz Institute for Immunotherapy, Regensburg, Germany.ORCID 0000-0003-2239-3282
June Ereño-OrbeaCancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0002-5076-2105
Endika Prieto-FernándezTumor Immunology and Immunotherapy, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID 0000-0001-8378-1495
Asis PalazonCancer Glycoimmunology Lab, Centre for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain.ORCID 0000-0002-7172-7229
Funding
Diputación Foral de Bizkaia (Bizkaiko Foru Aldundia) 6/12/TT/2023/00001Eusko Jaurlaritza (Gobierno Vasco) PRE_2019_1_0320Fundación Científica Asociación Española Contra el Cáncer (AECC) LABAE211744PALAFundación Científica Asociación Española Contra el Cáncer (AECC) PRDVZ19003BOSCFundación Científica Asociación Española Contra el Cáncer (AECC) PRDVZ21640DEBLFundación Científica Asociación Española Contra el Cáncer (AECC) TALEN245896PEREFundación Fero (Fundació Fero) XVI BECA FEROHORIZON EUROPE European Research Council (ERC) ERC-2018-StG 804236-NEXTGEN-IOIkerbasque, Basque Foundation for Science (Ikerbasque) Ikerbasque Research Associate ProfessorIkerbasque, Basque Foundation for Science (Ikerbasque) Ikerbasque Research Professor"la Caixa" Foundation ("la Caixa") LCF/BQ/DR20/11790022"la Caixa" Foundation ("la Caixa") LCF/BQ/PR24/12050010"la Caixa" Foundation ("la Caixa") LCF/PR/HR21/52410009Ministerio de Ciencia, Innovación y Universidades (MCIU) CEX2021-001136-SMinisterio de Ciencia, Innovación y Universidades (MCIU) CNS2023-145146Ministerio de Ciencia, Innovación y Universidades (MCIU) JDC2022-048612-IMinisterio de Ciencia, Innovación y Universidades (MCIU) PID2019-107956RA-I00Ministerio de Ciencia, Innovación y Universidades (MCIU) PID2023-147399NB-I00Ministerio de Ciencia, Innovación y Universidades (MCIU) PID2023-150777OB-I00Ministerio de Ciencia, Innovación y Universidades (MCIU) PRE2020-092342Ministerio de Ciencia, Innovación y Universidades (MCIU) RYC2018-024183-IMinisterio de Ciencia, Innovación y Universidades (MCIU) RYC2021-031213-ISchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF) Ambizione grant 180010
6 · The paper itself
Abstract
Chronic T-cell receptor (TCR) stimulation combined with adverse conditions in the tumor microenvironment (TME), such as hypoxia and nutrient deprivation, frequently results in T-cell exhaustion. Exhausted CD8+ T cells (TEX) experience oxidative stress, which causes an accumulation of oxidized proteins within the cells. We hypothesized that oxidized protein formation might exceed proteasomal degradation capacity, leading to their accumulation and impairing T-cell fitness. Single-cell transcriptomics analysis across 16 tumor types revealed increased expression of proteasome genes in TEX compared with non-TEX. In a robust in vitro model for the generation of human TEX, the cells exhibited hallmarks of exhaustion, with higher levels of reactive oxygen species-induced protein oxidation and increased expression of proteasome genes. Pharmacologic and genetic enhancement of proteasome activity delayed the onset of T-cell exhaustion, improved T-cell fitness, and translated into superior antitumor immunity and tumor control. These findings identify proteasome modulation as a promising strategy to counteract TME-driven T-cell dysfunction, potentially overcoming a major obstacle to the efficacy of cell-based immunotherapies in solid tumors. SIGNIFICANCE: Increased proteasome activity serves as a compensatory mechanism to manage oxidative stress, alleviate proteotoxicity, and prevent exhaustion in T cells, offering opportunities for cancer immunotherapy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Enhancing Proteasome Activity in T Cells Alleviates Exhaustion and Improves Antitumor Immunity. · full record | OpenQuestion